Literature DB >> 6238753

Characterization of the phenotype and function of lymphocytes infiltrating the salivary gland in patients with primary Sjogren syndrome.

R I Fox, T C Adamson, S Fong, C Young, F V Howell.   

Abstract

Monoclonal antibodies directed against T-cell subsets, B-cell subsets, and monocytes were used to characterize the cells infiltrating the salivary glands of patients with primary Sjogren syndrome (1 degree SS). Analysis of stained frozen tissue sections and lymphocyte suspensions derived from salivary glands revealed the majority of infiltrating cells to be T cells (reactive with antibodies SC1 and Leu 4) of the Leu 3a+ subset (greater than 70% reactive). Of particular interest, a high frequency of Ia+ T cells (up to 50% of T cells) and B cells reactive with antibody B532 (5-15% of infiltrating cells) were found in salivary gland lymphocytes (SGL) but not in peripheral blood lymphocytes (PBL) of the same patients. Our finding that the phenotype of SGL was significantly different from PBL emphasizes the need to characterize lymphocytes at the site of tissue destruction. In vitro functional assays demonstrated that the OKT4+ SGL exhibited T-helper activity but not natural killer, antibody-dependent cellular cytotoxicity, or cytotoxic T-lymphocyte activity. Of note, rheumatoid factor (IgM anti-IgG) was produced by SGL but not by the corresponding PBL. Our studies on SG-lymphocyte function represent an early step in elucidating the cellular and subcellular events responsible for this autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6238753

Source DB:  PubMed          Journal:  Diagn Immunol        ISSN: 0735-3111


  12 in total

Review 1.  Natural killer cells and autoimmunity.

Authors:  E Grunebaum; E Malatzky-Goshen; Y Shoenfeld
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

2.  CD166 expression, characterization, and localization in salivary epithelium: implications for function during sialoadenitis.

Authors:  Syed M A Abidi; Mohammad K Saifullah; Marie D Zafiropulos; Cara Kaput; Michael A Bowen; Calvin Cotton; Nora G Singer
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

Review 3.  Th17 cells in autoimmune diseases.

Authors:  Lei Han; Jing Yang; Xiuwen Wang; Dan Li; Ling Lv; Bin Li
Journal:  Front Med       Date:  2015-02-04       Impact factor: 4.592

Review 4.  The T cell in Sjogren's syndrome: force majeure, not spectateur.

Authors:  Namrata Singh; Philip L Cohen
Journal:  J Autoimmun       Date:  2012-06-17       Impact factor: 7.094

5.  Ruxolitinib inhibits IFNγ-stimulated Sjögren's salivary gland MSC HLA-DR expression and chemokine-dependent T cell migration.

Authors:  Sara S McCoy; Maxwell Parker; Ilya Gurevic; Rahul Das; Andrea Pennati; Jacques Galipeau
Journal:  Rheumatology (Oxford)       Date:  2022-10-06       Impact factor: 7.046

6.  Increased epithelial expression of HLA-DQ and HLA-DP molecules in salivary glands from patients with Sjögren's syndrome compared with obstructive sialadenitis.

Authors:  P S Thrane; T S Halstensen; H R Haanaes; P Brandtzaeg
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

7.  High salivary soluble L-selectin and interleukin-7 levels in Asian Indian patients with primary Sjögren's syndrome.

Authors:  Jayakanthan Kabeerdoss; Pulukool Sandhya; Santosh Kumar Mandal; Mahasampath Gowri; Debashish Danda
Journal:  Clin Rheumatol       Date:  2016-09-12       Impact factor: 2.980

8.  T cell receptor repertoire of infiltrating T cells in lips of Sjögren's syndrome patients.

Authors:  T Sumida; F Yonaha; T Maeda; E Tanabe; T Koike; H Tomioka; S Yoshida
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

Review 9.  Potential therapeutic approach for the hormonal treatment of lacrimal gland dysfunction in Sjögren's syndrome.

Authors:  D A Sullivan; E H Sato
Journal:  Clin Immunol Immunopathol       Date:  1992-07

Review 10.  T Helper 17 Cells in Primary Sjögren's Syndrome.

Authors:  Kiyoshi Matsui; Hajime Sano
Journal:  J Clin Med       Date:  2017-07-05       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.